SCIRENT is excited to participate at the TCT Conference from October 23-26, 2023, in San Francisco. The Transcatheter Cardiovascular Therapeutics (TCT) conference, hosted by the
Roswell, Georgia – 9 October, 2023 – Roivios Ltd., a medical device company pioneering a revolutionary treatment to reduce poor surgical outcomes associated with Acute
SCIRENT will be participating in the renowned ESC Congress in Amsterdam from 25th to 28th August 2023. This prestigious event is a powerful platform for
Save the dates in your agenda and join us in Prague from 20 to 23 May 2023 for the ESC Heart Failure Association (HFA) annual meeting
SCIRENT is thrilled to announce that we will be attending several high-ranking cardiovascular conferences in 2023. Meet our team to discover how SCIRENT, a specialized
SCIRENT, a full-service contract research organization (CRO) specializing in cardiovascular trials, is joining forces with CCS, a US-based cardiovascular clinical research organization, at HFSA Annual Scientific
SCIRENT is excited to participate at the ESC Congress 2022 in Barcelona, which is taking place from 26-29 August 2022. Please book an appointment with
10.11.2021. SCIRENT is attending the American Heart Association’s Scientific Sessions, AHA 2021, from November 13-15, 2021 as a proud exhibitor. Visit our booth and connect
BERLIN, Sept. 21, 2021 /PRNewswire/ — SCIRENT, an international full-service cardiovascular contract research organization (CRO), is proud to appoint Dr. Maximilian Posch as Chief Medical
Berlin Heals’ innovative implantable C-MIC device delivers encouraging clinical results in the treatment of heart failure.
The entire landscape of hospital-based clinical trials dramatically changed when COVID-19 singlehandedly stopped the global recruitment of ongoing cardiovascular trials. Heart failure clinical trials were
SCIRENT, a full-service contract research organization (CRO) specialized in cardiovascular trials, and Virtonomy, a pioneer in developing data-driven clinical trials using virtual patients, announced today
Global medical technology and innovation company, LivaNova PLC, conducts the large medical device study ANTHEM-HFrEF to evaluate whether autonomic regulation therapy will benefit patients with
Drug developer Berlin Cures has launched a phase IIa trial for its β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDNA product BC 007.
The global COVID-19 pandemic has largely impacted the healthcare system and also the conduct of clinical trials. Many sponsors have had to adapt clinical trial
